INS and type 2 diabetes mellitus: To determine if the insulin sensitizing effects of TZDs are associated with changes in S1P levels in vivo, we measured plasma S1P in a small cohort of obese T2D subjects at baseline and after 4 months of rosiglitazone treatment.